Scholarlink

Background <p>Candidiasis is humans’ most common oral fungal infection and is a major opportunistic fungal infection with significant morbidity and mortality, particularly in immunocompromised patients, highlighting its clinical importance worldwide. This study investigated the antifungal effect of nystatin, fluconazole, cinnamaldehyde, and nano-cinnamaldehyde on candidiasis.</p> Methods <p>In this in vitro study, nano-cinnamaldehyde formulations were prepared using span60, tween60, and cholesterol for fabrication of noisome vesicles by the ethanol injection technique. The optimum formulation (cinnosome 2) was prepared with 100&#xa0;mg Span 60, 100&#xa0;mg Tween 60, and 50&#xa0;mg cholesterol with 5&#xa0;ml of ethanol. The size and particle dispersion index (PDI) of nanoparticles were measured using Dynamic Light Scattering technique, the zeta potential was measured using Zetasizer Nano ZS, and the amount of nano-cinnamaldehyde release was measured using dialysis by USP2 dissolution device. Twenty <i>Candida</i> species isolates, including <i>C. albicans</i>, <i>Pichia kudriavzevii</i>,<i> Nakaseomyces glabratus</i>, and <i>C. tropicalis</i>, were obtained from clinical samples, cultured in malt extract agar medium, and fungal suspensions were prepared in RPMI medium. For antifungal evaluation, the broth microdilution test was performed, and the MIC was read after 24&#xa0;h. Differences between groups were determined by Mann-Whitney and Kruskal-Wallis tests at a significance level of 0.05 via GraphPad Prism 6 and SPSS 22 software.</p> Results <p>Among the five niosomal formulations, the optimal nanoparticle showed a mean size of 228.75 ± 2.38&#xa0;nm, PDI of 0.24 ± 0.01, zeta potential of -10.87 ± 1.09 mV, and encapsulation efficiency (EE%) of 66.71 ± 3.93%. The size of the nanoparticles varied from 137 to 297&#xa0;nm among the formulations, and the particle size increased significantly with the amount of cholesterol. Nystatin, fluconazole and nano-cinnamaldehyde showed the best antifungal property with the lowest geometric mean (GM), 0.177&#xa0;µg/mL, 0. 308&#xa0;µg/mL and 0.554&#xa0;µg/mL, respectively, followed by cinnamaldehyde (2.732&#xa0;µg/mL) and carrier (2.828&#xa0;µg/mL).</p> Conclusions <p>According to the MIC<sub>50</sub> and MIC<sub>90</sub> values, it was found that nystatin, fluconazole, nano-cinnamaldehyde, cinnamaldehyde and carrier have the highest to the lowest antifungal property, respectively. Findings revealed that nano-cinnamaldehyde exhibited excellent antifungal activity against more than 65% of <i>Candida</i> isolates, indicating its promise as a potent alternative for managing oral candidiasis.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antifungal efficacy of cinnamaldehyde and nano-cinnamaldehyde particles against candidiasis: an in-vitro study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Tahereh Molania,
  • Majid Saeedi,
  • Katayoun Morteza-Semnani,
  • Reza Negarandeh,
  • Abolfazl Hosseinnataj,
  • Anahita Lotfizadeh,
  • Hossein Fadaei,
  • Ali Jafari,
  • Maede Salehi,
  • Iman Haghani

摘要

Background

Candidiasis is humans’ most common oral fungal infection and is a major opportunistic fungal infection with significant morbidity and mortality, particularly in immunocompromised patients, highlighting its clinical importance worldwide. This study investigated the antifungal effect of nystatin, fluconazole, cinnamaldehyde, and nano-cinnamaldehyde on candidiasis.

Methods

In this in vitro study, nano-cinnamaldehyde formulations were prepared using span60, tween60, and cholesterol for fabrication of noisome vesicles by the ethanol injection technique. The optimum formulation (cinnosome 2) was prepared with 100 mg Span 60, 100 mg Tween 60, and 50 mg cholesterol with 5 ml of ethanol. The size and particle dispersion index (PDI) of nanoparticles were measured using Dynamic Light Scattering technique, the zeta potential was measured using Zetasizer Nano ZS, and the amount of nano-cinnamaldehyde release was measured using dialysis by USP2 dissolution device. Twenty Candida species isolates, including C. albicans, Pichia kudriavzevii, Nakaseomyces glabratus, and C. tropicalis, were obtained from clinical samples, cultured in malt extract agar medium, and fungal suspensions were prepared in RPMI medium. For antifungal evaluation, the broth microdilution test was performed, and the MIC was read after 24 h. Differences between groups were determined by Mann-Whitney and Kruskal-Wallis tests at a significance level of 0.05 via GraphPad Prism 6 and SPSS 22 software.

Results

Among the five niosomal formulations, the optimal nanoparticle showed a mean size of 228.75 ± 2.38 nm, PDI of 0.24 ± 0.01, zeta potential of -10.87 ± 1.09 mV, and encapsulation efficiency (EE%) of 66.71 ± 3.93%. The size of the nanoparticles varied from 137 to 297 nm among the formulations, and the particle size increased significantly with the amount of cholesterol. Nystatin, fluconazole and nano-cinnamaldehyde showed the best antifungal property with the lowest geometric mean (GM), 0.177 µg/mL, 0. 308 µg/mL and 0.554 µg/mL, respectively, followed by cinnamaldehyde (2.732 µg/mL) and carrier (2.828 µg/mL).

Conclusions

According to the MIC50 and MIC90 values, it was found that nystatin, fluconazole, nano-cinnamaldehyde, cinnamaldehyde and carrier have the highest to the lowest antifungal property, respectively. Findings revealed that nano-cinnamaldehyde exhibited excellent antifungal activity against more than 65% of Candida isolates, indicating its promise as a potent alternative for managing oral candidiasis.

Clinical trial number

Not applicable.